326. Osteopetrosis Clinical trials / Disease details

Clinical trials : 20 / Drugs : 51 - (DrugBank : 14) / Drug target genes : 17 - Drug target pathways : 81

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02666768 (ClinicalTrials.gov)	February 22, 2016	23/6/2015	ACTIMMUNE in Intermediate Osteopetrosis	Open-label Early Phase 2 Study With a Single Arm of Interferon Gamma-1b Treatment of Osteopetrosis	Osteopetrosis	Drug: Interferon gamma -1b	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center	University of Minnesota;Horizon Pharma Ireland, Ltd., Dublin Ireland	Completed	1 Year	N/A	All	5	Phase 2	United States
2	NCT02584608 (ClinicalTrials.gov)	January 1, 2016	20/10/2015	Use of ACTIMMUNE in Patients With ADO2	Phase 2a Study of Interferon Gamma-1b for the Treatment of Autosomal Dominant Type 2 Osteopetrosis	Autosomal Dominant Osteopetrosis Type 2	Drug: ACTIMMUNE	Indiana University	Horizon Pharma Ireland, Ltd., Dublin Ireland	Completed	3 Years	65 Years	All	12	Phase 2	United States
3	NCT00043329 (ClinicalTrials.gov)	January 2002	7/8/2002	Post Marketing Surveillance Study of Actimmune in Patients With Severe, Malignant Osteopetrosis	Post-Marketing Surveillance Study of Actimmune (Interferon Gamma-1b) in Patients With Severe Malignant Osteopetrosis	Osteopetrosis	Drug: Actimmune Registry	InterMune	NULL	Completed	N/A	N/A	Both	6		United States